603229 奥翔药业
已收盘 12-19 15:00:00
资讯
新帖
简况
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%
证券之星 · 12-01
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%
每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员
证券之星 · 11-23
每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员
奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%
证券之星 · 11-18
奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%
奥翔药业：选举职工代表董事
证券日报网 · 11-18
奥翔药业：选举职工代表董事
每周股票复盘：奥翔药业（603229）拟取消监事会
证券之星 · 11-09
每周股票复盘：奥翔药业（603229）拟取消监事会
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%
证券之星 · 11-04
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%
奥翔药业：10月份公司未实施股份回购
证券日报网 · 11-03
奥翔药业：10月份公司未实施股份回购
每周股票复盘：奥翔药业（603229）Q3净利降23.33%
证券之星 · 11-02
每周股票复盘：奥翔药业（603229）Q3净利降23.33%
奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”
证券之星 · 11-01
奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”
图解奥翔药业三季报：第三季度单季净利润同比下降23.33%
证券之星 · 10-30
图解奥翔药业三季报：第三季度单季净利润同比下降23.33%
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%
证券之星 · 10-30
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%
每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元
证券之星 · 10-12
每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，10月9日股价上涨0.1%
证券之星 · 10-09
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，10月9日股价上涨0.1%
奥翔药业(603229.SH)：甲磺酸伊马替尼片获药品注册证书
智通财经 · 09-16
奥翔药业(603229.SH)：甲磺酸伊马替尼片获药品注册证书
每周股票复盘：奥翔药业（603229）Q2净利降25.54%
证券之星 · 08-31
每周股票复盘：奥翔药业（603229）Q2净利降25.54%
奥翔药业(603229.SH)发布半年度业绩，归母净利润1.69亿元，同比下降5.83%
智通财经 · 08-28
奥翔药业(603229.SH)发布半年度业绩，归母净利润1.69亿元，同比下降5.83%
奥翔药业收盘上涨5.51%，滚动市盈率47.68倍，总市值101.79亿元
金融界 · 08-25
奥翔药业收盘上涨5.51%，滚动市盈率47.68倍，总市值101.79亿元
奥翔药业涨5.07% 创新管线与集采扰动共振
智选洞察 · 08-11
奥翔药业涨5.07% 创新管线与集采扰动共振
奥翔药业股价下跌5.05% 医药集采与资金流出施压
智选洞察 · 08-05
奥翔药业股价下跌5.05% 医药集采与资金流出施压
机械设备板块走高，医药股回调
中国基金报 · 08-04
机械设备板块走高，医药股回调
暂无数据
公司概况
公司名称：
浙江奥翔药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-05-09
主营业务：
浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药、医药中间体。
发行价格：
7.81
{"stockData":{"symbol":"603229","market":"SH","secType":"STK","nameCN":"奥翔药业","latestPrice":9.61,"timestamp":1766127600000,"preClose":9.47,"halted":0,"volume":3695612,"delay":0,"changeRate":0.0148,"floatShares":830000000,"shares":830000000,"eps":0.2227,"marketStatus":"已收盘","change":0.14,"latestTime":"12-19 15:00:00","open":9.53,"high":9.65,"low":9.45,"amount":35396000,"amplitude":0.0211,"askPrice":9.61,"askSize":109,"bidPrice":9.6,"bidSize":379,"shortable":0,"etf":0,"ttmEps":0.2227,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.47,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":10.42,"lowLimit":8.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":830297145,"isCdr":false,"pbRate":3.4,"roa":"--","peRate":43.152223,"roe":"8.86%","epsLYR":0.25,"committee":-0.106791,"marketValue":7979000000,"turnoverRate":0.0045,"status":0,"floatMarketCap":7979000000},"requestUrl":"/m/hq/s/603229/tweets","defaultTab":"tweets","newsList":[{"id":"2588700725","title":"奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588700725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588700725?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:55","pubTimestamp":1764582929,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，奥翔药业报收于9.9元，较前一交易日上涨0.41%，最新总市值为82.2亿元。该股当日开盘9.92元，最高9.96元，最低9.85元，成交额达3563.5万元，换手率为0.43%。公司近日发布关于以集中竞价交易方式回购公司股份的进展公告。公告显示，浙江奥翔药业股份有限公司于2025年1月24日召开董事会，审议通过回购股份方案，拟用于股权激励和/或员工持股计划。2025年11月未实施回购。回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2585106805","title":"每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106805?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:24","pubTimestamp":1763843054,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，奥翔药业报收于9.67元，较上周的10.55元下跌8.34%。本周关注点公司公告汇总：奥翔药业取消监事会，修订公司章程及相关内部制度。公司公告汇总奥翔药业第四届董事会第十次会议于2025年11月18日召开，审议通过《关于确认董事会审计委员会成员和召集人的议案》。刘瑜原为非职工代表董事，变更后董事会仍为9名成员，职工代表董事及兼任高管的董事人数未超过半数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2584510956","title":"奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584510956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584510956?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:42","pubTimestamp":1763476945,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，奥翔药业报收于10.29元，较前一交易日下跌0.77%，最新总市值为85.44亿元。该股当日开盘10.33元，最高10.43元，最低10.23元，成交额达7276.43万元，换手率为0.85%。近日，奥翔药业发布2025年第一次临时股东大会决议公告，公司于2025年11月18日召开2025年第一次临时股东大会，出席会议的股东所持表决权股份占公司总股本的54.7441%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2584276953","title":"奥翔药业：选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2584276953","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584276953?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:42","pubTimestamp":1763473320,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月18日晚间，奥翔药业发布公告称，公司于2025年11月18日在公司新办公楼一楼会议室召开职工代表大会，选举刘瑜先生担任公司第四届董事会职工代表董事。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-18/doc-infxvtuw3896357.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-18/doc-infxvtuw3896357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2582864919","title":"每周股票复盘：奥翔药业（603229）拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864919","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582864919?lang=zh_cn&edition=full","pubTime":"2025-11-09 05:05","pubTimestamp":1762635920,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，奥翔药业报收于10.08元，较上周的10.25元下跌1.66%。本周，奥翔药业11月6日盘中最高价报10.5元。奥翔药业当前最新总市值83.69亿元，在化学制药板块市值排名68/151，在两市A股市值排名2211/5166。公司拟取消监事会，其职权由董事会审计委员会行使，现任监事将解任。会议采取现场与网络投票相结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2580753991","title":"奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580753991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580753991?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:43","pubTimestamp":1762267403,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，奥翔药业报收于10.02元，较前一交易日下跌2.34%，最新总市值为83.2亿元。该股当日开盘10.2元，最高10.29元，最低9.93元，成交额达9393.98万元，换手率为1.13%。公司近日发布公告称，将于2025年11月18日召开2025年第一次临时股东大会，审议《关于取消监事会并修订〈公司章程〉的议案》和《关于修订公司部分内部管理制度的议案》。公告显示，奥翔药业拟取消监事会，其原有职权由董事会审计委员会行使，现任监事将予以解任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2580496214","title":"奥翔药业：10月份公司未实施股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2580496214","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580496214?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:38","pubTimestamp":1762177080,"startTime":"0","endTime":"0","summary":"证券日报网讯11月3日晚间，奥翔药业发布公告称，2025年10月，公司未实施股份回购。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcvcm0806235.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcvcm0806235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2580787408","title":"每周股票复盘：奥翔药业（603229）Q3净利降23.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580787408","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580787408?lang=zh_cn&edition=full","pubTime":"2025-11-02 09:12","pubTimestamp":1762045932,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥翔药业报收于10.25元，较上周的10.14元上涨1.08%。本周，奥翔药业10月31日盘中最高价报10.28元。股本股东变化截至2025年9月30日，奥翔药业股东户数为3.2万户，较6月30日增加1708户，增幅5.64%。业绩披露要点奥翔药业2025年三季报显示，前三季度主营收入6.46亿元，同比下降6.4%；归母净利润2.07亿元，同比下降9.59%；扣非净利润1.83亿元，同比下降13.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2580692414","title":"奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580692414","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580692414?lang=zh_cn&edition=full","pubTime":"2025-11-01 05:49","pubTimestamp":1761947386,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示奥翔药业（603229）公布了一项国际专利申请，专利名为“卢美哌隆中间体及其制备方法”，专利申请号为PCT/CN2025/090864，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来奥翔药业已公布的国际专利申请2个，较去年同期减少了33.33%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了5633.8万元，同比增39.4%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100004820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2579148279","title":"图解奥翔药业三季报：第三季度单季净利润同比下降23.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579148279","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579148279?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:25","pubTimestamp":1761823555,"startTime":"0","endTime":"0","summary":"证券之星消息，奥翔药业2025年三季报显示，前三季度公司主营收入6.46亿元，同比下降6.4%；归母净利润2.07亿元，同比下降9.59%；扣非净利润1.83亿元，同比下降13.83%；其中2025年第三季度，公司单季度主营收入1.64亿元，同比下降17.01%；单季度归母净利润3768.58万元，同比下降23.33%；单季度扣非净利润3210.87万元，同比下降20.42%；负债率23.3%，投资收益1924.35万元，财务费用-429.16万元，毛利率56.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000039916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229"],"gpt_icon":0},{"id":"2579115149","title":"奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579115149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579115149?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:58","pubTimestamp":1761818313,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，奥翔药业报收于9.99元，较前一交易日下跌1.48%，最新总市值为82.95亿元。近日，奥翔药业发布关于召开2025年第一次临时股东大会的通知。审议事项包括关于取消监事会并修订《公司章程》的议案，以及修订《股东会议事规则》《董事会议事规则》《独立董事工作制度》等多项内部管理制度的议案。其中，取消监事会并修订《公司章程》为特别决议议案，对中小投资者单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000035353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2574146339","title":"每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574146339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574146339?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:45","pubTimestamp":1760211914,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，奥翔药业报收于10.17元，较上周的10.2元下跌0.29%。本周，奥翔药业10月9日盘中最高价报10.3元。奥翔药业当前最新总市值84.44亿元，在化学制药板块市值排名68/150，在两市A股市值排名2192/5158。截至2025年9月30日，公司累计回购股份5,201,200股，占总股本0.63%，已支付总金额50,006,023.36元，回购最高价为11.39元/股，最低价为7.52元/股。2025年9月未实施回购。上述回购进展符合相关规定，公司将继续根据市场情况推进回购并履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2574304471","title":"奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，10月9日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574304471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574304471?lang=zh_cn&edition=full","pubTime":"2025-10-09 17:42","pubTimestamp":1760002975,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘，奥翔药业报收于10.21元，较前一交易日上涨0.1%，最新总市值为84.77亿元。该股当日开盘10.29元，最高10.3元，最低10.09元，成交额达6691.94万元，换手率为0.79%。近日，奥翔药业发布关于以集中竞价交易方式回购公司股份的进展公告。2025年9月未实施回购。上述回购符合相关规定。公司将继续根据市场情况推进回购并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900023725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2567477177","title":"奥翔药业(603229.SH)：甲磺酸伊马替尼片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567477177","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567477177?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:12","pubTimestamp":1758010332,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业(603229.SH)公告，公司全资子公司浙江麒正药业有限公司(简称“麒正药业”)收到国家药品监督管理局核准签发的甲磺酸伊马替尼片《药品注册证书》。公告显示，甲磺酸伊马替尼片是全球首个抗肿瘤分子靶向药物，用于治疗慢性粒细胞白血病(CML)急变期、加速期或α-干扰素治疗失败后的慢性期患者、不能手术切除或发生转移的恶性胃肠道间质肿瘤(GIST)患者。其有效成分伊马替尼是一种酪氨酸激酶抑制剂，可以有效地抑制费城染色体基因，使磷酸化反应无法被催化、染色体的功能丧失，从而抑制不正常的白血球增生;同时也可与酪氨酸激酶活性位置结合，并阻止其活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥翔药业(603229.SH)：甲磺酸伊马替尼片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2563302833","title":"每周股票复盘：奥翔药业（603229）Q2净利降25.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563302833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563302833?lang=zh_cn&edition=full","pubTime":"2025-08-31 07:57","pubTimestamp":1756598229,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，奥翔药业报收于11.18元，较上周的11.62元下跌3.79%。本周，奥翔药业8月26日盘中最高价报12.51元，股价触及近一年最高点。股本股东变化截至2025年6月30日，奥翔药业股东户数为3.03万户，较3月31日减少516户，减幅1.67%。业绩披露要点奥翔药业2025年中报显示，主营收入4.82亿元，同比下降2.14%；归母净利润1.69亿元，同比下降5.83%；扣非净利润1.51亿元，同比下降12.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2562085522","title":"奥翔药业(603229.SH)发布半年度业绩，归母净利润1.69亿元，同比下降5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562085522","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562085522?lang=zh_cn&edition=full","pubTime":"2025-08-28 15:47","pubTimestamp":1756367226,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业(603229.SH)披露2025年半年度报告，报告期公司实现营收4.82亿元，同比下降2.14%;归母净利润1.69亿元，同比下降5.83%;扣非净利润1.51亿元，同比下降12.29%;基本每股收益0.20元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"奥翔药业(603229.SH)发布半年度业绩，归母净利润1.69亿元，同比下降5.83%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603229"],"gpt_icon":0},{"id":"2562245128","title":"奥翔药业收盘上涨5.51%，滚动市盈率47.68倍，总市值101.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562245128","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562245128?lang=zh_cn&edition=full","pubTime":"2025-08-25 19:07","pubTimestamp":1756120058,"startTime":"0","endTime":"0","summary":"8月25日，奥翔药业今日收盘12.26元，上涨5.51%，滚动市盈率PE达到47.68倍，创17天以来新低，总市值101.79亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均65.87倍，行业中值38.88倍，奥翔药业排名第101位。截至2025年一季报，共有1家机构持仓奥翔药业，其中基金1家，合计持股数2.77万股，持股市值0.00亿元。浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/25190752672876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2558313966","title":"奥翔药业涨5.07% 创新管线与集采扰动共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2558313966","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558313966?lang=zh_cn&edition=full","pubTime":"2025-08-11 13:50","pubTimestamp":1754891404,"startTime":"0","endTime":"0","summary":"奥翔药业股价今日大幅上涨，截至13点49分，最新价报11.19元/股，涨幅达5.07%。资金博弈与政策扰动共振奥翔药业近日净流入受多重因素叠加影响。第十一批药品集采将抗肿瘤药物纳入范围，公司肝病类产品占营收28.56%，集采竞价规则变化引发利润空间担忧，部分资金选择避险。创新管线与国际化双轮驱动估值长期来看，奥翔药业估值中枢取决于研发突破与全球供应链布局。未来临床数据披露与集采政策传导节奏将成股价关键变量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811135009a6def6db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811135009a6def6db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2557348356","title":"奥翔药业股价下跌5.05% 医药集采与资金流出施压","url":"https://stock-news.laohu8.com/highlight/detail?id=2557348356","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557348356?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:57","pubTimestamp":1754359068,"startTime":"0","endTime":"0","summary":"奥翔药业股价大幅下跌，最新价10.90元/股，跌幅达5.05%。资金博弈与政策扰动共振奥翔药业近日股价波动受多重因素交织影响。第十一批药品集采将抗肿瘤药物纳入范围，公司肝病类产品占营收比例达28.56%，竞价规则调整或压制原料药利润空间，引发资金避险需求。程序化交易监管新规实施后，7月17日换手率升至1.42%，净流出折价5.3%，显示活跃资金对政策敏感度提升。创新突围与全球布局重塑价值锚点奥翔药业长期逻辑聚焦创新药研发与全球化能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805095759a4757c6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805095759a4757c6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","603229","BK0239"],"gpt_icon":1},{"id":"2556309870","title":"机械设备板块走高，医药股回调","url":"https://stock-news.laohu8.com/highlight/detail?id=2556309870","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556309870?lang=zh_cn&edition=full","pubTime":"2025-08-04 13:00","pubTimestamp":1754283600,"startTime":"0","endTime":"0","summary":"盘面上，航天军工、贵金属、纺织服饰、银行、机械设备等板块走高，军工信息化、黄金珠宝、工业母机等概念股活跃；医药股回调，零售、通信、教育等板块不振。机械设备板块走高游戏股拉升8月4日上午，除国防军工板块火热外，机械设备板块同步走高。医药股回调创新药、CRO跌幅居前8月4日上午，医药生物板块整体下行，创新药、减肥药、CRO等概念股不振。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508041308469731f485&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508041308469731f485&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688136","02577","09939","600828","01347","BK1161","BK1163","BK1515","600774","603716","603229","BK1574","605298","600977","601929"],"gpt_icon":1}],"profile":{"ret":0,"serverTime":1766147329067,"stockEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0797},{"period":"3month","weight":-0.1199},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.0939},{"period":"ytd","weight":-0.0419}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江奥翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31998人(较上一季度增加5.64%)","perCapita":"25948股","listingDate":"2017-05-09","address":"浙江省台州市临海市化学原料药基地临海园区东海第四大道5号","registeredCapital":"83029万元","survey":" 浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药、医药中间体。","listedPrice":7.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥翔药业,603229,奥翔药业股票,奥翔药业股票老虎,奥翔药业股票老虎国际,奥翔药业行情,奥翔药业股票行情,奥翔药业股价,奥翔药业股市,奥翔药业股票价格,奥翔药业股票交易,奥翔药业股票购买,奥翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}